Prognostic factors and secondary malignancies in childhood medulloblastoma

T. Stavrou, C. M. Bromley, H. S. Nicholson, J. Byrne, R. J. Packer, A. M. Goldstein, G. H. Reaman

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose: Little is known of the outcome of long-term survivors of childhood medulloblastoma, one of the most common pediatric malignancies. To determine the potential for secondary malignancies, a retrospective outcome evaluation in 88 consecutive cases of childhood medulloblastoma was performed. Patients and Methods: The records of all patients with childhood medulloblastoma diagnosed at Children's National Medical Center in Washington, DC from 1969 through 1997 were reviewed. Results: The median follow-up time was 92 months (range 6-257 months). Overall survival was 59% at 5 years and 52% at 10 years. Univariate analysis showed that age at diagnosis, extent of surgical resection, presence of metastatic disease (M stage), ventriculoperitoneal shunt placement within 30 days from diagnosis, posterior fossa radiation therapy dose, and adjuvant chemotherapy significantly affected survival. Although based on small numbers, the risk of second neoplasms was significantly increased in this cohort. Multiple basal cell carcinomas developed in the areas of radiation therapy in two patients; these patients also had nevoid basal cell carcinoma syndrome (NBCCS) diagnosed. One other patient died of glioblastoma multiforme 8 years after treatment of medulloblastoma. A meningioma developed in another patient 10 years after radiation therapy. Conclusion: As survival of medulloblastoma patients improves, increased surveillance regarding secondary malignancies is required, especially because radiation-induced tumors may occur many years after treatment. These two cases of NBCCS also illustrate the importance of considering the concomitant diagnosis of NBCCS in young patients with medulloblastoma. In those patients, alternative therapy should be considered to minimize radiation therapy-related sequelae.

Original languageEnglish (US)
Pages (from-to)431-436
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume23
Issue number7
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Medulloblastoma
Basal Cell Nevus Syndrome
Neoplasms
Radiotherapy
Survival
Ventriculoperitoneal Shunt
Second Primary Neoplasms
Meningioma
Adjuvant Chemotherapy
Glioblastoma
Complementary Therapies
Survivors
Radiation
Pediatrics

Keywords

  • Medulloblastoma
  • Nevoid basal cell carcinoma syndrome
  • Prognostic factors
  • Secondary malignancies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Stavrou, T., Bromley, C. M., Nicholson, H. S., Byrne, J., Packer, R. J., Goldstein, A. M., & Reaman, G. H. (2001). Prognostic factors and secondary malignancies in childhood medulloblastoma. Journal of Pediatric Hematology/Oncology, 23(7), 431-436. https://doi.org/10.1097/00043426-200110000-00008

Prognostic factors and secondary malignancies in childhood medulloblastoma. / Stavrou, T.; Bromley, C. M.; Nicholson, H. S.; Byrne, J.; Packer, R. J.; Goldstein, A. M.; Reaman, G. H.

In: Journal of Pediatric Hematology/Oncology, Vol. 23, No. 7, 2001, p. 431-436.

Research output: Contribution to journalArticle

Stavrou, T, Bromley, CM, Nicholson, HS, Byrne, J, Packer, RJ, Goldstein, AM & Reaman, GH 2001, 'Prognostic factors and secondary malignancies in childhood medulloblastoma', Journal of Pediatric Hematology/Oncology, vol. 23, no. 7, pp. 431-436. https://doi.org/10.1097/00043426-200110000-00008
Stavrou, T. ; Bromley, C. M. ; Nicholson, H. S. ; Byrne, J. ; Packer, R. J. ; Goldstein, A. M. ; Reaman, G. H. / Prognostic factors and secondary malignancies in childhood medulloblastoma. In: Journal of Pediatric Hematology/Oncology. 2001 ; Vol. 23, No. 7. pp. 431-436.
@article{7c1b6729f22243639b763b8c9781c4ba,
title = "Prognostic factors and secondary malignancies in childhood medulloblastoma",
abstract = "Purpose: Little is known of the outcome of long-term survivors of childhood medulloblastoma, one of the most common pediatric malignancies. To determine the potential for secondary malignancies, a retrospective outcome evaluation in 88 consecutive cases of childhood medulloblastoma was performed. Patients and Methods: The records of all patients with childhood medulloblastoma diagnosed at Children's National Medical Center in Washington, DC from 1969 through 1997 were reviewed. Results: The median follow-up time was 92 months (range 6-257 months). Overall survival was 59{\%} at 5 years and 52{\%} at 10 years. Univariate analysis showed that age at diagnosis, extent of surgical resection, presence of metastatic disease (M stage), ventriculoperitoneal shunt placement within 30 days from diagnosis, posterior fossa radiation therapy dose, and adjuvant chemotherapy significantly affected survival. Although based on small numbers, the risk of second neoplasms was significantly increased in this cohort. Multiple basal cell carcinomas developed in the areas of radiation therapy in two patients; these patients also had nevoid basal cell carcinoma syndrome (NBCCS) diagnosed. One other patient died of glioblastoma multiforme 8 years after treatment of medulloblastoma. A meningioma developed in another patient 10 years after radiation therapy. Conclusion: As survival of medulloblastoma patients improves, increased surveillance regarding secondary malignancies is required, especially because radiation-induced tumors may occur many years after treatment. These two cases of NBCCS also illustrate the importance of considering the concomitant diagnosis of NBCCS in young patients with medulloblastoma. In those patients, alternative therapy should be considered to minimize radiation therapy-related sequelae.",
keywords = "Medulloblastoma, Nevoid basal cell carcinoma syndrome, Prognostic factors, Secondary malignancies",
author = "T. Stavrou and Bromley, {C. M.} and Nicholson, {H. S.} and J. Byrne and Packer, {R. J.} and Goldstein, {A. M.} and Reaman, {G. H.}",
year = "2001",
doi = "10.1097/00043426-200110000-00008",
language = "English (US)",
volume = "23",
pages = "431--436",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Prognostic factors and secondary malignancies in childhood medulloblastoma

AU - Stavrou, T.

AU - Bromley, C. M.

AU - Nicholson, H. S.

AU - Byrne, J.

AU - Packer, R. J.

AU - Goldstein, A. M.

AU - Reaman, G. H.

PY - 2001

Y1 - 2001

N2 - Purpose: Little is known of the outcome of long-term survivors of childhood medulloblastoma, one of the most common pediatric malignancies. To determine the potential for secondary malignancies, a retrospective outcome evaluation in 88 consecutive cases of childhood medulloblastoma was performed. Patients and Methods: The records of all patients with childhood medulloblastoma diagnosed at Children's National Medical Center in Washington, DC from 1969 through 1997 were reviewed. Results: The median follow-up time was 92 months (range 6-257 months). Overall survival was 59% at 5 years and 52% at 10 years. Univariate analysis showed that age at diagnosis, extent of surgical resection, presence of metastatic disease (M stage), ventriculoperitoneal shunt placement within 30 days from diagnosis, posterior fossa radiation therapy dose, and adjuvant chemotherapy significantly affected survival. Although based on small numbers, the risk of second neoplasms was significantly increased in this cohort. Multiple basal cell carcinomas developed in the areas of radiation therapy in two patients; these patients also had nevoid basal cell carcinoma syndrome (NBCCS) diagnosed. One other patient died of glioblastoma multiforme 8 years after treatment of medulloblastoma. A meningioma developed in another patient 10 years after radiation therapy. Conclusion: As survival of medulloblastoma patients improves, increased surveillance regarding secondary malignancies is required, especially because radiation-induced tumors may occur many years after treatment. These two cases of NBCCS also illustrate the importance of considering the concomitant diagnosis of NBCCS in young patients with medulloblastoma. In those patients, alternative therapy should be considered to minimize radiation therapy-related sequelae.

AB - Purpose: Little is known of the outcome of long-term survivors of childhood medulloblastoma, one of the most common pediatric malignancies. To determine the potential for secondary malignancies, a retrospective outcome evaluation in 88 consecutive cases of childhood medulloblastoma was performed. Patients and Methods: The records of all patients with childhood medulloblastoma diagnosed at Children's National Medical Center in Washington, DC from 1969 through 1997 were reviewed. Results: The median follow-up time was 92 months (range 6-257 months). Overall survival was 59% at 5 years and 52% at 10 years. Univariate analysis showed that age at diagnosis, extent of surgical resection, presence of metastatic disease (M stage), ventriculoperitoneal shunt placement within 30 days from diagnosis, posterior fossa radiation therapy dose, and adjuvant chemotherapy significantly affected survival. Although based on small numbers, the risk of second neoplasms was significantly increased in this cohort. Multiple basal cell carcinomas developed in the areas of radiation therapy in two patients; these patients also had nevoid basal cell carcinoma syndrome (NBCCS) diagnosed. One other patient died of glioblastoma multiforme 8 years after treatment of medulloblastoma. A meningioma developed in another patient 10 years after radiation therapy. Conclusion: As survival of medulloblastoma patients improves, increased surveillance regarding secondary malignancies is required, especially because radiation-induced tumors may occur many years after treatment. These two cases of NBCCS also illustrate the importance of considering the concomitant diagnosis of NBCCS in young patients with medulloblastoma. In those patients, alternative therapy should be considered to minimize radiation therapy-related sequelae.

KW - Medulloblastoma

KW - Nevoid basal cell carcinoma syndrome

KW - Prognostic factors

KW - Secondary malignancies

UR - http://www.scopus.com/inward/record.url?scp=0034761908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034761908&partnerID=8YFLogxK

U2 - 10.1097/00043426-200110000-00008

DO - 10.1097/00043426-200110000-00008

M3 - Article

VL - 23

SP - 431

EP - 436

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 7

ER -